Key figures

31st largest pharmaceutical group worldwide
2nd largest pharmaceutical group in France.
5th leading pharmaceutical group in cardiology worldwide
(IQVIA Analytics September 2020)

100 million patient treated each day worldwide with Servier Group medicines.

98% of active ingredients of brand-name medicines manufactured in France.

€4.7 billion (2019/20 group revenue)

23% of group revenue (from brand-name medicines) invested in R&D in 2019/2020

150 countries in which the Group's medicines are distributed.

96% of Group revenue (from brand-name medicines) generated outside France.

22,500 employees, including 4,900 in France.

3 therapeutic areas
oncology, immune-inflammatory and neurodegenerative diseases, cardiometabolism.